iBio, Inc. (IBIO) vs Pliant Therapeutics, Inc. (PLRX)
A side-by-side comparison of iBio, Inc. and Pliant Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
IBIO
iBio, Inc.
$1.05HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
PLRX
Pliant Therapeutics, Inc.
$1.03HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — IBIO vs PLRX
growth of $100 · dividends reinvested · last 6yIBIO -99.9% (-66.8%/yr)PLRX -95.2% (-39.6%/yr)PLRX compounded faster over this window
Log scale — wide-divergence pair
IBIO PLRX
IBIO vs PLRX: by the numbers
- •IBIO is the larger company ($68M vs $64M market cap).
- •Both run net losses; PLRX's is the smaller (0.00% vs -33044.00% net margin).
Metrics side by side
Valuation
| Metric | IBIO | PLRX |
|---|---|---|
| P/S ratio | 675.23 | N/A |
| P/B ratio | 0.79 | 0.43 |
Profitability
| Metric | IBIO | PLRX |
|---|---|---|
| Gross margin | 100.00% | 0.00% |
| Operating margin | -35141.00% | 0.00% |
| Net margin | -33044.00% | 0.00% |
| ROE | -38.55% | -62.81% |
| ROIC | -40.22% | -56.22% |
Growth (annualized)
| Metric | IBIO | PLRX |
|---|---|---|
| Revenue CAGR (5Y) | -46.91% | N/A |
| Total return CAGR (5Y) | -70.43% | -43.17% |
Frequently asked
- How have IBIO and PLRX total returns compared?
- Over the past 5 years, IBIO delivered -70.43% and PLRX delivered -43.17% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.